BELLUS Health to Present Clinical Data from Phase 2b SOOTHE Trial of BLU-5937 at the European Respiratory Society International Congress 2022 Pharmaceutical Investing
Gilead Announces First Global Regulatory Approval of Sunlenca® , the Only Twice-Yearly HIV Treatment Option Pharmaceutical Investing
Lobe Sciences Announces Update on Corporate Slide Deck Highlighting its Psilocin Compounds and Development Plans Pharmaceutical Investing
Ginkgo Bioworks Announces Strategic Purchase of Epidemiological Data Infrastructure Assets Company News
Awakn Life Sciences Signs Second Licensing Partnership Agreement and Expands Commercial Operations Into Canada Company News
Gilead Sciences Announces Collaboration With Morehouse School of Medicine and Xavier University of Louisiana College of Pharmacy to Address Inequities in HIV Care Pharmaceutical Investing
Bristol Myers Squibb Completes Acquisition of Turning Point Therapeutics, Expanding Precision Oncology Portfolio Pharmaceutical Investing
Cybin and Clinilabs Granted Schedule I DEA License for CYB003 Phase 1/2a First-In-Human Clinical Trial Company News
Marvel Biosciences Reports MB-204 as Highly Effective at Treating Autism Behaviours in Shank3 Mouse Model
Marvel Biosciences Signs Letter of Intent with Novatech for Phase 1 Trial of MB-204 and Provides Corporate Update
